Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2022
Alexion and Chugai settle Ultomiris patent disputes
Alexion, part of AstraZeneca's Rare Disease group, entered into a settlement agreement with Chugai resolving their patent disputes related to Ultomiris. The parties took steps to withdraw patent infringement proceedings filed in US and Japanese courts. Alexion will make a single payment of $775 million in the second quarter of 2022.
2022
AstraZeneca and Chugai settle Ultomiris patent litigation
AstraZeneca announced an agreement with Chugai Pharmaceutical resolving all patent disputes related to Ultomiris. Alexion, AstraZeneca's Rare Disease group, will make a single payment of $775 million in the second quarter of 2022.
2021
Fresenius filed patent review petitions challenging rheumatoid arthritis patents
Fresenius Kabi USA and Fresenius Kabi SwissBioSim filed Inter Partes Review petitions challenging two patents assigned to Chugai, Roche, and Genentech, asserting that the relevant claims were invalid as anticipated or obvious. These are allegations in the petitions, not a reported decision on their merits.